Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now that's funny.
Just my 2 cents. Everything about the launch of this product is scalable. Getting to more than 100 people to support the product will only be necessary if there are more than a few units, installed simultaneously, across a wide geographical area. A few teams of 5-6 people, on-site can cover a lot of area with procedures in place for remote support/diagnostics. So if there are 9(?) test units/sites, then that's 45-55 people. Then 10-15 more at the HQ Engineering Lab to support them. I would guess that it will be the pre-procedure diagnostics that will be go/no-go tools when test units are installed in the field.
I'm going to assume that this device will be modular and can be maintained by swapping out components at the sub-assembly level and with ports to upgrade the software.
It's still a big question as to how this will shake out. My hope is that they can sell units overseas sooner, and establish credibility with the US based cadaver studies at the same time.
I'm looking at this as a long play and hoping for the short BO/MA.
I don't think this is dead money, because there are still more moves to be made from here to FDA/CE, or foreign sales.
And yes, I think ISRG is an element to this pps manipulation.
IMO.
Regards,
BK
This may only be a one day coincidence, but if those that want to sell would let the "Ask" fly, seems that there's a lot of buyers today. Would be curious to see what the reaction would be with a high $.68-$.69 Ask. JMO
Regards,
Bk
When I do the math it looks like it's $16M U.S.
Regards,
BK
If you do the math of $.0746 x 16M, and the same pps for another 11M, the total amount of the investment is about $21M. The pps is declared in the company announcement. I just think the numbers in the announcement make sense. It would require clarification from the source. IMO.
Regards,
BK
Point of reference. Applying 4 CE in 2017.
With CE mark they can start to sell in Europe (&Canada?). Not sure about that, but it will have a positive affect on pps. Earlier than when FDA approval is issued, but proven surgical technology. IMO.
Regards,
BK
From our friends at Stockhouse.
World Congress of Podiatry - May 26-27
Theralase is there, right in the middle of the crowd ...
International Federation of Podiatrists - World Congress of Podiatry - Montreal, May 26-28 2016
World Congress of Podiatry – Montreal 2016 - Confirmed Exhibitors
Read more at http://www.stockhouse.com/companies/bullboard/tltff#FWr73QGFOIGv8lai.99
Regards,
BK
Well I'm not saying that I'm 100% happy about managements performance, but was commenting about the FDA requirements. It's not a cut-and-dry process. If the predicate device is daVinci, then there are 10 years of functionality to mimic. That's a tall order in 1 year. And if there was a misunderstanding that SPORT could be FDA approved on a "task oriented performance basis" then the rejection of Suribot was very beneficial as it provided more detail about what is necessary do to get approved.
The pps of this company does reek of manipulation. And I do agree that the cc created more questions than answers. I also agree that the AGM will be very eventful with all of the outstanding questions, and need for further details about the OEM, and financing going forward. It's a hell of a device and again, if there were any flaws or omissions in functionality, we would have heard about it during or after SAGES.
Is it still possible to submit a lesser version for CE mark and begin to sell outside US, sooner than when the OEM partnered version is made available? Or use the OEM version with fewer indications and go for V1.2 when fully completed? Why not sell the OEM version with 2 to 4 main indications, and provide additional indications as V1.2 as a chargeable upgrade? Brings the product before the FDA sooner, and to market quicker. Just a thought.
JMO.
Respectfully,
BK
I'm not so sure about why Titan should have known about the details of the new standards.
I've worked with the US federal government on software, hardware and secure access for both.
Just because the gov't solicits your input, and you have several meetings to stay abreast of the agency direction, does not mean that you will have advanced notice of all of the requirements. Even if you did have all of the requirements, they may not have been able to integrate them in such a short timeframe. Much of product development is sequencial, so A,B,C needs to be completed before you can design, manufacture and test L,M,N,O,P. Not to mention the software that would control the new pieces.
And.... some of those requirements may be in the public sector, but Titan has to design and develop them a different way so as to not trigger a patent infringement.
Please keep in mind how many surgeons demo'd SPORT and there were no public discussions of disappointment about the functionality. If there was a flaw or glaring omission, I think someone would have said something by now. JMO.
Regards,
BK
I'm in complete agreement with your comments.
Regards,
BK
Way too much drama.
Demand? Is that how you go about getting someone that you've never met and/or never spoken to before to speak with you? How about asking a respectable question in a professional manor?
$5.00 more in the jar.
Up to $35.00 now.
Regards,
BK
Hi Suerte88. Now I don't get it.
You asked for subject matter that was pertinent to the shift in the time line. I said that I found interesting opinion from a specific source on another site, that I thought had logical elements as a reasonable explanation for the extended submission. That's what you're reading. Hope this is useful for you.
Regards,
BK
Oldest & IMO best comments at the very bottom, then more current as you read to the top.
Regards,
BK
Aubrey
May 05, 2016 - 02:20 AM 167 Reads
Post# 24843238
Rate this post
image: http://www.stockhouse.com/Stockhouse/images/stars-mask.png
4 stars
v
this aint a delay
this aint a delay...ffs ..they upgraded the sterile properties of the devise, and re testing the system. No one said they didn't pass an inspection. Material engineering is allways a moving target! upgrade evrything, every chance you get
the tech in this vid is fun...watch this...you will start upgrading too
I do read the Stockhouse Bullboard.
If anyone would like another source for TLT product opinion and viewing, and I don't take most of what's shared on that board as factual. There is some science presented for subject matter. There's also a poster that makes a few good points as to what they think has created the most recent time line change. Please go to "Aubrey." And read her posts. They seem logical to me.
FWIW.
Regards,
BK
If my memory is correct, someone from this board spoke with JH at SAGES and asked about a RS. JH pulled out a letter requesting it be considered from a shareholder, and replied. No. Anyone recall that exchange of messages on this board?
Regards,
BK
I sent it as a "reply" to your previous gmail message.
Lemmi know.
Regards,
BK
I'm pm'ing you with a question please
regards
BK
More volume today based on the announcement of increased number of cancer targets. I expected a small bounce prior to ITA announcement. Than another bounce once patient trials begin, for early adopters and those that buy early and sell on the news. Then another bounce once phase-1b trial data is announced. But... I see your point and have watched it too. I still think pps goes above$1.00 US prior to phase 1b trial results. Because when the results are positive, then we get a lot of exposure.
GLTA.
Regards,
BK
It came from Stockhouse TITXF Bullboard a few days ago. I can't pull it up now for some reason. Don't know why.
Regards,
BK
I'm surprised to see someone post that, with the whole board watching.???
Anyone that wants to PM me - bigkahuna57@gmail.com
Thanks
Regards,
BK
Flower? My mind is in too many places and don't follow.
Regards,
BK
Very good news!
UHN and Dr. Lothar Lilge, PhD, Senior Scientist at UHN wouldn't continue to partner with TLT without supportive evidence that there's a basis from which to continue NMIB and expand into multiple cancer applications. These incremental steps make sense to broaden the scope after the ITA and phase 1b trials.
And I do think that once ITA is approved there will be an increase in pps. My crystal ball is not clear as to how far. I'm hoping for $.50-$.60 based on the cancer division alone. And another $.20-$30 for the TLT-2000 sales.
Regards,
BK
Very good news!
UHN and Dr. Lothar Lilge, PhD, Senior Scientist at UHN wouldn't continue to partner with TLT without supportive evidence that there's a basis from which to continue NMIB and expand into multiple cancer applications. These incremental steps make sense to broaden the scope after the ITA and phase 1b trials.
And I do think that once ITA is approved there will be an increase in pps. My crystal ball is not clear as to how far. I'm hoping for $.50-$.60 based on the cancer division alone. And another $.20-$30 for the TLT-2000 sales.
Regards,
BK
I've seen that gum at 7-11 and didn't know of the license agreement with ATTBF. I asked how's it selling just being curious and the clerk said people like it. I was really surprised. Could be something to really look forward to. IMO
Regards,
BK
IITF, I'm in agreement with you. And, I don't see how JH can know that there won't be any offers prior to FDA. I really think the litmus test will be CE mark because it permits the sale of units except for in the US. I don't know how many companies with the requisite cash/equity necessary to make a $B M/A outside of the US, but I'd venture a guess that there are more than a few. Here's to a very short time line for cadaver studies! IMO
Regards,
BK
There's marketing going on albeit behind the scenes.
I would think that they have the attendee list from SAGES and they're reaching out to those 800 professionals that were in attendance. They may not inform us, but that's why they attended. Those lists are gold - to be mined. Then they work backward after following up with those that will engage in a followup conversation regarding SPORT to create word-of-mouth momentum. There's also those hospitals from where our SAB is affiliated. Those surgeons were chosen specifically for their professional expertise and industry reputations. IMO
They have to be actively engaged to take the pulse of the market place to find out and prioritize the number of units necessary for the cadaver study sites, possible additional field trial sites (may not be the same facilities as cadaver studies but would commit to purchase with an on site proof of performance) and then the production schedule. The best case scenario would be that there are more hospitals that want the SPORT than they can produce and support with a reasonable ramp up schedule. Then SPORT's go on backorder and there's a waiting list, just like Harley's. I've lived these cycles for decades when launching new products (not medical).
I would venture a guess (pun intended) that there's venture capital lurking, but they want too much of the pie. Distribution agreements would be a great way to provide alternate funding, but those agreements better have buyout clauses in them, because some company could panic and just pull the trigger. And it would be with very little notice. Yes I do recall the buyout M/A agreement. IMO
Once we get into cadaver studies and apply for the CE mark, this will get very, very interesting. IMO
Regards,
BK
I read it as they needed the REB and ITA approvals prior to the clinical trials. They got the REB approval and the last step - 3.5 going to 4 is the ITA approval.
I think we get action once the ITA is approved prior to the trial and again once the trial starts. There will be another step up once the trial starts for those that want to be in early prior to the phase 1 trial assessments. JMO
Regards,
BK
Me too. But I thought that I'd let you know that there are ways to overcome your concern.
Regards,
BK
$5 more. That's $30. Looks like ur on your way to a good bar tab!
Regards,
BK
They can purchase a performance bond, which is like insurance to hold the manufacturer to the established features of a statement of work. Many companies that get large awards from the federal government are required to have one at the time of award or within 30 days of award. And..... I wouldn't expect any hospital to get a SPORT without an initial trial/installation and proof of concept at that facility. Or possibly observe a live procedure prior to ordering one.
Regards,
BK
Good step in the right direction.
Needed to get this approval prior to ITA.
Happy, happy, happy.
Regards,
BK
This should be a positive day.
I would think that anyone invested in robotic surgery would view the unfortunate news of one of our "competitors" as a very positive element in our road to higher pps. There are many different elements in the competitive landscape, but one is now no longer an issue. I'm guessing that the design freeze is a combination of end effector creation and software for additional motion. Just a guess. IMO
Once these are behind us, and the field trial/cadaver studies begin - we'll be much better off pps wise and investor perception wise. Very soon.
Regards,
BK
Nice observation. I was thinking about how that would be a great delivery medium. Already in production, has a customer base, but now with a special ingredient. No more difficult to produce except for the "special" quality control and distribution. IMO
Regards,
BK
I'm trying to understand the logic behind the points that are being made that JH and others are working (or not) to artificially keep the pps low. While the pps is low, I'm not connecting the dots as to the "why" anyone would do that. To my point - Titan isn't selling their shares to keep us around $.70. Someone has to be selling those shares before someone else can buy them. So... what's the motive? Who has the means to pull off something like this? Who's got the funding to throw $$$ around to keep us artificially low???? If that "someone" has bought a 1M shares, that would last about 10 - 20 trading days. I keep coming back to how the decisions are made to buy and sell from the MM's. Who's pulling their strings? Could it be large funds that are heavily invested in ISRG? Just to get a few more $M out of the stock before we are certified? idk, but I don't think it's management. I think that's plausible because of the monopoly that exists at this time. And..... what about ISRG options that haven't hit their strike point yet. That's a motive. IMO.
We are talking pennies here because $.02 of a million shares is only $20K right? Compared to an ISRG $600 stock with a position of several hundred thousand or more shares.
Further, a 1 indication MIS robot would not be much of a competitor, but a multiple indication MIS robot has A LOT more market appeal. Who else would benefiting from a low pps. Again, idk, but I don't think it's management. IMO
Regards,
BK
That's a nice visual. Hope it all works out.
Regards,
BK
I don't think publishing or producing interviews from the SAB, or comments from professionals that were in attendance at SAGES would be out of bounds. All involved know that they can't sell the device, but advertising or roundtable discussion would be marketing 101. There were 800 Surgeons at SAGES? I wonder if any hospitals beyond those being chosen for the field trial units have been contacted to line up budgets for next year? That would be very important to know so they could plan for production/builds. IMO
Regards,
BK
I don't think this a "chicken-or-egg" dilemma. Milestones will need to be met or significant progress/cadaver studies or partnership announcements will need to show up first before we get to the level of pps necessary to uplist. It's a domino affect. Soon. Very soon, we'll start to move up as the calendar starts to work more in our favor. Good PR updates will be of significant benefit too. IMO
Regards,
BK
I'm thinking glitch. Yahoo Finance shows somewhere in $.63. I confirmed with Vanguard $.71 US.
Regards,
BK
I'm inclined to agree with those points. Maybe there are 7 (or 9?) units to use as both trial units and on-site demo units. Demo units sell product a lot faster than videos and brochures. Cadaver studies should move the timeline up, so says my "logic." Again, I'm not in this field so it's "uneducated" logic. Would like to hear more from our professional board members. Thanks.
Regards,
BK
Thank you for that clarification. Do you or does anyone know what the minimum requirements are for passing and getting task based approval(s)? Are they the same for the FDA and HC? Again thank you to those that have the knowledge and share it with those of us that don't.
Regards,
BK
I'm thinking that they're working on the cadaver studies and possibly coordinating those with the SAIL training? Would make sense to me to video those and use them for compare and contrast during training. What would keep TITAN from going for 3-4 "main" indications with the largest market applications, to get the device approved sooner, and continue to work on the balance of indications to round out the marketing and full approvals? Just a thought.
Regards,
BK